Anju Software has announced that Steve Rosenberg has joined the company's Board of Directors.
MMS Holdings announced the addition of Kevin Chartier, PhD, as Principal Advisor of Biostatistics and Submissions Planning.
Worldwide Clinical Trials announced the addition of Andrew Cunningham, PhD, Vice President, Bioanalytical; Ingela Danielsson-Sanden, MD, PhD, MBA, CHCQM, as Vice President of Early Phase Medical Management; and Austin Sansbury, MBA, PMP, as Strategic Projects Officer.
Greenphire announced that it has appointed Alan Matuszak as its new Chief Technology Officer.
THREAD announced the appointment of Scott Pearson as chief product officer.
IDDI celebrates its 30th anniversary this year.
CluePoints has announced it has won, in collaboration with BioNTech and Pfizer, the Clinical Advance of the Year category - COVID-19 Pandemic Special Recognition Award at the 17th Annual Scrip Awards.
CB Insights named Tendo Systems to its third annual Digital Health 150.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.